[Science, marketing and pharmacovigilance: the example of topical calcineurin inhibitors].
Paul
C
C
D000279:Administration, Cutaneous; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D065095:Calcineurin Inhibitors; D002648:Child; D003879:Dermatologic Agents / Q000009:adverse effects*; D017277:Drug Approval; D016903:Drug Monitoring; D005060:Europe; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D040541:Marketing; D009369:Neoplasms / Q000139:chemically induced; D011358:Product Surveillance, Postmarketing; D018570:Risk Assessment; D012307:Risk Factors; D012586:Science; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives; D014481:United States
D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus